Quick Takeaways:
- VETARYS and Antigenesis Biologics have announced a research collaboration and an option for an exclusive license for a fusion-protein combination immunotherapy targeting solid tumors in dogs.
- Antigenesis is adapting advances in human immunotherapy to develop antibody treatments for companion animals. Its candidate combines two immunotherapies that showed improved survival and tumor shrinkage in a mouse melanoma model.
- VETARYS aims to develop a subcutaneous treatment that primary-care veterinarians can administer, complementing specialist oncology services. The collaboration seek to address limited treatment options and gaps in access to cancer care for dogs.
Why It Matters?
VETARYS and Antigenesis are advancing a potential canine cancer immunotherapy that adapts human oncology approaches for veterinary use. A subcutaneous formulation suitable for primary-care clinics could broaden access beyond specialist centers and differentiate the treatment pathway. However, the mouse-model findings require validation in dogs, with clinical efficacy, safety and licensing terms shaping commercial potential.
Source: PRnewswire
